HealthRX.com · Printable question sheet
Question sheet for your autoimmune care team before any MOTS-c use
Take this to the specialist who manages your autoimmune condition. It lists your current immune-modifying treatment, what the MOTS-c research did and did not test, and the questions that matter when nothing has been studied in people like you.
Your condition
Diagnosis and year diagnosed
Current activityflare, stable, remission
Specialist who manages it, and phone number
Infections in the past year that needed treatment
Immune-modifying treatment you use now
Include steroids, biologic injections or infusions, JAK inhibitors, methotrexate and other DMARDs.
| Medicine | Type | Amount and schedule | Started | Prescriber |
|---|---|---|---|---|
What the MOTS-c research covers
- The autoimmune finding comes from NOD mice, a model of type 1 diabetes, that were given MOTS-c.[1]
- In people, the same study only measured blood MOTS-c, which was lower in 10 people with type 1 diabetes than in healthy controls; nobody was given the peptide.[1]
- FDA found no clinical studies or human exposure data for MOTS-c by any route.[2]
- FDA notes that antibodies against an injected peptide can cause loss of effect or even neutralize the body's own version of the peptide, and that injection under the skin may strengthen this response.[3]
Questions for your specialist
- Has any study given MOTS-c to people with my condition, or alongside my current treatment?
- Could a reaction to an injected peptide be mistaken for a flare, or hide one?
- Does my treatment raise my risk from any new injection, such as infection or injection-site reactions?
- Which symptoms or test results should make me call you straight away?
- Is there an approved option, with data in my condition, for the goal I have in mind?
Symptom notes to share at the visit
| Date | Symptom or change | Joint, skin, gut or other site | Anything new that week |
|---|---|---|---|
Sources for the facts on this sheet
- Kong BS, Min SH, Lee C, Cho YM. Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes. Cell Rep 2021. PMID 34320351. https://pubmed.ncbi.nlm.nih.gov/34320351/
- U.S. Food and Drug Administration. July 23, 2026 Meeting of the Pharmacy Compounding Advisory Committee: FDA Presentations (MOTS-c (free base) and MOTS-c acetate). Accessed 2026-10-18. https://www.fda.gov/media/193773/download
- U.S. Food and Drug Administration. FDA Briefing Document: MOTS-c-Related Bulk Drug Substances (MOTS-c (free base) and MOTS-c acetate), Pharmacy Compounding Advisory Committee, July 23-24, 2026. Accessed 2026-10-18. https://www.fda.gov/media/193347/download
This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.